A human seminal plasma protein blocks the motility of human spermatozoa.
An inhibitor of the motility of demembranated spermatozoa has been shown to be present in human seminal plasma. This seminal plasma motility inhibitor (SPMI) was purified to apparent homogeneity and tested on intact human spermatozoa. Motility parameters of spermatozoa incubated with the sperm motility inhibitor were evaluated with the video automated Cell Soft system. SPMI decreased the percentage of motile spermatozoa in a dose-dependent manner and motility was completely blocked in the presence of 1600 units/ml. Sperm velocity and beat/cross frequency showed a similar progressive decrease as the inhibitor was augmented. However, linearity was essentially not affected. The effects of SPMI on the percentage of motile spermatozoa increased with the time of contact between the inhibitor and spermatozoa. After 120 min., the IC50 was 35% lower than that observed at five min. The presence of seminal plasma did not prevent the inhibitory effects of the seminal plasma factor on sperm motility parameters. On the contrary, a potentiating effects was observed. The data suggest that the SPMI could play a significant role in cases of infertility caused by asthenospermia.
Iwamoto
T
T
Urology Research Laboratory, Royal Victoria Hospital, Montreal, Quebec, Canada.
Gagnon
C
C
D006801:Humans; D008297:Male; D029584:Prostatic Secretory Proteins; D011506:Proteins / Q000302:isolation & purification / Q000494:pharmacology*; D012661:Semen / Q000032:analysis*; D029589:Seminal Plasma Proteins; D013078:Sperm Immobilizing Agents / Q000302:isolation & purification*; D013081:Sperm Motility / Q000187:drug effects
D029584:Prostatic Secretory Proteins; D011506:Proteins; D029589:Seminal Plasma Proteins; D013078:Sperm Immobilizing Agents; C043076:beta-microseminoprotein